Abelman, R. O., McLaughlin, S., Fell, G. G., Garrido-Castro, A. C., Lynce, F., Trippa, L., Poorvu, P. D., Rosenstock, A. S., Medford, A. J., Wander, S. A., Comander, A. H., Isakoff, S. J., Moy, B., Tung, N. M., Mittendorf, E. A., Ellisen, L., Tolaney, S. M., Bardia, A., Spring, L. (2025). A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.511